Published in J Immunol on March 01, 1970
Leukocyte locomotion and chemotaxis. New methods for evaluation, and demonstration of a cell-derived chemotactic factor. J Exp Med (1973) 14.88
The role of the macrophage in wound repair. A study with hydrocortisone and antimacrophage serum. Am J Pathol (1975) 6.42
The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med (1971) 2.95
Pathologic mechanisms in neutrophil-mediated injury. Am J Pathol (1972) 2.57
Interactions of C-reactive protein with the complement system. I. Protamine-induced consumption of complement in acute phase sera. J Exp Med (1974) 2.47
Complement-derived leukotactic factors in inflammatory synovial fluids of humans. J Clin Invest (1971) 2.35
Mechanism for the inflammatory response in primate lungs. Demonstration and partial characterization of an alveolar macrophage-derived chemotactic factor with preferential activity for polymorphonuclear leukocytes. J Clin Invest (1977) 2.24
Acute inflammation. A review. Am J Pathol (1977) 2.06
Human alveolar macrophage-derived chemotactic factor for neutrophils. Stimuli and partial characterization. J Clin Invest (1980) 2.04
Elastase of Pseudomonas aeruginosa: inactivation of complement components and complement-derived chemotactic and phagocytic factors. Infect Immun (1974) 1.99
Chemotactic factor inactivator in normal human serum. J Clin Invest (1973) 1.93
Mediation systems in bacterial lipopolysaccharide-induced hypotension and disseminated intravascular coagulation. I. The role of complement. J Exp Med (1975) 1.91
Leukotactic factors elaborated by virus-infected tissues. J Exp Med (1972) 1.89
The development of atypical hemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol (2010) 1.88
Leukotactic factors in health and disease. Am J Pathol (1971) 1.71
Studies on the pathogenesis of the adult respiratory distress syndrome. J Clin Invest (1982) 1.68
Venous endothelial damage produced by massive sticking and emigration of leukocytes. Am J Pathol (1974) 1.48
Chemotactic factor inactivators of human granulocytes. J Clin Invest (1977) 1.40
Chemotactic factor inactivation by the myeloperoxidase-hydrogen peroxide-halide system. J Clin Invest (1979) 1.39
Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis. Adv Exp Med Biol (2012) 1.34
Suppression of immune complex-induced inflammation by the chemotactic factor inactivator. J Clin Invest (1977) 1.33
Comparison of subcutaneous and intraperitoneal staphylococcal infections in normal and complement-deficient mice. Infect Immun (1976) 1.33
Platelet-dependent generation of chemotactic activity in serum. J Exp Med (1973) 1.18
Bacillus Calmette-Guérin-stimulated neutrophils release chemotaxins for monocytes in rabbit pleural spaces and in vitro. J Clin Invest (1985) 1.18
Digestion of the fifth component of complement by leukocyte enzymes. Sequential generation of chemotactic activities for leukocytes and for tumor cells. Am J Pathol (1979) 1.16
In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M, and A against Pseudomonas aeruginosa lipopolysaccharide. Infect Immun (1989) 1.14
Polymorphonuclear leukocyte and monocyte chemoattractants produced by human fibroblasts. J Clin Invest (1979) 1.10
Effects of intra-articular corticosteroids in vivo on synovial fluid variables in rheumatoid synovitis. Ann Rheum Dis (1974) 1.08
Normal pregnancy is characterized by systemic activation of the complement system. J Matern Fetal Neonatal Med (2005) 1.06
Generation of anaphylatoxins by human beta-tryptase from C3, C4, and C5. J Immunol (2008) 1.05
Pulmonary response of fifth component of complement-sufficient and -deficient mice to hyperoxia. J Clin Invest (1984) 1.01
Role of C5 and recruited neutrophils in early clearance of nontypable Haemophilus influenzae from murine lungs. Infect Immun (1985) 0.99
Increased concentration of the complement split product C5a in acute pyelonephritis during pregnancy. J Matern Fetal Neonatal Med (2005) 0.97
Inhibition of neutrophil exocytosis ameliorates acute lung injury in rats. Shock (2013) 0.97
Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor. Am J Pathol (2000) 0.95
Anaphylatoxins in preterm and term labor. J Perinat Med (2005) 0.95
Modulation of human eosinophil polymorphonuclear leukocyte migration and function. Am J Pathol (1976) 0.93
Prolonged survival of kidney xenografts in leucopenic rabbits. Immunology (1971) 0.92
Targeting complement component 5a promotes vascular integrity and limits airway remodeling. Proc Natl Acad Sci U S A (2013) 0.90
Characterization of three macrophage chemotactic factors from PPD-induced delayed hypersensitivity reaction sites in guinea pigs, with special reference to a chemotactic lymphokine. Am J Pathol (1982) 0.89
Preeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split products. J Matern Fetal Neonatal Med (2010) 0.88
A recombinant vaccine effectively induces c5a-specific neutralizing antibodies and prevents arthritis. PLoS One (2010) 0.88
Kidney injury accelerates cystogenesis via pathways modulated by heme oxygenase and complement. J Am Soc Nephrol (2012) 0.84
A chemotactic inhibitor in synovial fluid. Immunology (1983) 0.84
Fragment Bb: evidence for activation of the alternative pathway of the complement system in pregnant women with acute pyelonephritis. J Matern Fetal Neonatal Med (2010) 0.83
Interaction of the terminal complement components C5b-9 with synovial fibroblasts: binding to the membrane surface leads to increased levels in collagenase-specific mRNA. Immunology (1993) 0.82
Chemotactic factors released in culture by intact developing and healing skin lesions produced in rabbits by the irritant sulfur mustard. Inflammation (1997) 0.82
Immunopathology of the lung: a review. Am J Pathol (1979) 0.81
Role of leucocytes in free radical production during myocardial revascularisation. Heart (1997) 0.80
Persistent biological reactivity of quartz in the lung: raised protease burden compared with a non-pathogenic mineral dust and microbial particles. Br J Ind Med (1991) 0.79
Autologous Serum and Plasma Skin Tests in Chronic Spontaneous Urticaria: A Reappraisal. Indian Dermatol Online J (2017) 0.75
Further studies on the chemotactic factor of complement and its formation in vivo. Immunology (1966) 7.59
Bacterial factors chemotactic for polymorphonuclear leukocytes. Am J Pathol (1968) 5.77
Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-alpha, LPS, and IL-1 beta. Science (1989) 4.99
A plasmin-split fragment of C'3 as a new chemotactic factor. J Exp Med (1967) 4.94
The deactivation of rabbit neutrophils by chemotactic factor and the nature of the activatable esterase. J Exp Med (1968) 4.79
A neutrophil chemotactic factor from human C'5. J Immunol (1969) 4.46
Role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions. Am J Pathol (1982) 4.38
Leukotactic factor produced by sensitized lymphocytes. Science (1969) 3.95
Mechanisms of the inhibition of chemotaxis by phosphonate esters. J Exp Med (1967) 3.87
Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun (1988) 3.63
Adhesion molecules and inflammatory injury. FASEB J (1994) 3.53
Acute immunologic pulmonary alveolitis. J Clin Invest (1974) 3.53
The isolation and partial characterization of neutrophil chemotactic factors from Escherichia coli. J Immunol (1975) 3.50
Intravascular activation of complement and acute lung injury. Dependency on neutrophils and toxic oxygen metabolites. J Clin Invest (1982) 3.49
Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc Natl Acad Sci U S A (1999) 3.49
Purification and identification of formyl-methionyl-leucyl-phenylalanine as the major peptide neutrophil chemotactic factor produced by Escherichia coli. J Biol Chem (1984) 3.32
Length of uninterrupted CGG repeats determines instability in the FMR1 gene. Nat Genet (1994) 3.22
The production by antigen-stimulated lymphocytes of a leukotactic factor distinct from migration inhibitory factor. Cell Immunol (1970) 3.17
Partial biochemical characterization of the activated esterase required in the complement-dependent chemotaxis of rabbit polymorphonuclear leukocytes. J Exp Med (1967) 3.15
The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med (1971) 2.95
Chemotoxis of mononuclear cells. J Exp Med (1968) 2.95
Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo. Science (1993) 2.71
The chemosuppression of chemotaxis. J Exp Med (1966) 2.62
Evidence for role of hydroxyl radical in complement and neutrophil-dependent tissue injury. J Clin Invest (1983) 2.52
Protective effects of C5a blockade in sepsis. Nat Med (1999) 2.50
Role of endothelial-leukocyte adhesion molecule 1 (ELAM-1) in neutrophil-mediated lung injury in rats. J Clin Invest (1991) 2.50
Tissue injury caused by deposition of immune complexes is L-arginine dependent. Proc Natl Acad Sci U S A (1991) 2.49
Neutrophil-dependent acute lung injury. Requirement for P-selectin (GMP-140). J Clin Invest (1992) 2.47
Role of oxygen metabolites in immune complex injury of lung. J Immunol (1981) 2.39
Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J Biol Chem (1990) 2.37
In vitro and in vivo activity of a lymphocyte and immune complex-dependent chemotactic factor for eosinophils. J Exp Med (1971) 2.36
Complement-derived leukotactic factors in inflammatory synovial fluids of humans. J Clin Invest (1971) 2.35
Neutrophil aggregation and swelling induced by chemotactic agents. J Immunol (1977) 2.26
Evidence for soluble immune complexes in the pathogenesis of the glomerulonephritis of quartan malaria. Lancet (1969) 2.22
C3 leukotactic factors produced by a tissue protease. J Exp Med (1969) 2.19
Human herpesvirus 6 in salivary glands. Lancet (1990) 2.15
Biochemical demonstration of the activatable esterase of the rabbit netrophil involved in the chemotactic response. J Immunol (1970) 2.12
In vivo damage of rat lungs by oxygen metabolites. J Clin Invest (1981) 2.10
In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. J Clin Invest (1997) 2.04
Pulmonary endothelial cell killing by human neutrophils. Possible involvement of hydroxyl radical. Lab Invest (1985) 2.01
Bleomycin-induced pulmonary fibrosis in the rat: inhibition by indomethacin. Am J Pathol (1979) 1.96
Role for macrophage inflammatory protein-2 in lipopolysaccharide-induced lung injury in rats. J Immunol (1996) 1.95
C5a-induced expression of P-selectin in endothelial cells. J Clin Invest (1994) 1.93
Chemotactic factor inactivator in normal human serum. J Clin Invest (1973) 1.93
Chemotactic factor influences on the aggregation, swelling, and foreign surface adhesiveness of human leukocytes. Am J Pathol (1978) 1.91
Generation of chemotactic activity in rabbit serum by plasminogen-streptokinase mixtures. J Exp Med (1967) 1.90
Leukotactic factors elaborated by virus-infected tissues. J Exp Med (1972) 1.89
Neutropenia induced by systemic infusion of chemotactic factors. J Immunol (1977) 1.89
Molecular and clinical correlations of deletions leading to Duchenne and Becker muscular dystrophies. Neurology (1989) 1.88
Defective regulation of inflammatory mediators in Hodgkin's disease. Supernormal levels of chemotactic-factor inactivator. N Engl J Med (1974) 1.88
Tumor necrosis factor participates in the pathogenesis of acute immune complex alveolitis in the rat. J Clin Invest (1989) 1.86
Acute inflammatory pulmonary reactions induced by chemotactic factors. Am J Pathol (1979) 1.79
Impaired leucotactic responsiveness in a child with recurrent infections. Lancet (1969) 1.78
Selective neutrophil desensitization to chemotactic factors. J Cell Biol (1979) 1.77
Requirement and role of C5a in acute lung inflammatory injury in rats. J Clin Invest (1996) 1.77
Tumor necrosis factor alpha regulates in vivo intrapulmonary expression of ICAM-1. Am J Pathol (1993) 1.74
Leukotactic factors in health and disease. Am J Pathol (1971) 1.71
Impaired neutrophil chemotaxis in patients with juvenile and rapidly progressing periodontitis. J Periodontal Res (1979) 1.70
Inhibition of lung inflammatory reactions in rats by an anti-human IL-8 antibody. J Immunol (1993) 1.68
Studies on Antibacterial Products Formed by Molds: I. Aspergillic Acid, a Product of a Strain of Aspergillus Flavus. J Bacteriol (1943) 1.68
Neutrophil chemotactic factors and related clinical disorders. Arthritis Rheum (1970) 1.68
Molecular cloning and characterization of DEFCAP-L and -S, two isoforms of a novel member of the mammalian Ced-4 family of apoptosis proteins. J Biol Chem (2000) 1.66
Lung and dermal vascular injury produced by preformed immune complexes. Am Rev Respir Dis (1978) 1.64
Pathogenesis of the granulomatous lung diseases. Am Rev Respir Dis (1984) 1.64
C5 chemotactic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation. J Clin Invest (1979) 1.63
Isolation from human serum of an inactivator of bacterial lipopolysaccharide. Am J Pathol (1977) 1.58
Influence of inhibitors of cellular function on chemotactic factor-induced neutrophil aggregation. J Immunol (1977) 1.57
Two distinct chemotactic factor inactivators in human serum. J Immunol (1975) 1.55
Inhibition of in vivo and in vitro neutrophil responses to chemotactic factors by a competitive antagonist. J Immunol (1978) 1.55
Endothelial cell killing by neutrophils. Synergistic interaction of oxygen products and proteases. Am J Pathol (1989) 1.55
Chemotaxis of human eosinophils. Am J Pathol (1969) 1.54
Role of C5a in multiorgan failure during sepsis. J Immunol (2001) 1.53
Chemotaxis of rat lymphocytes. J Immunol (1977) 1.53
Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1. J Immunol (1995) 1.53
Role of macrophage inflammatory protein-1 alpha (MIP-1 alpha) in acute lung injury in rats. J Immunol (1995) 1.52
Biologic role of complement products. Complement-derived leukotactic activity extractable from lesions of immunologic vasculitis. J Immunol (1972) 1.51
Leukotactic dystunction in sarcoidosis. Ann Intern Med (1976) 1.50
Suppression by superoxide dismutase of immune-complex--induced pulmonary alveolitis and dermal inflammation. Am J Pathol (1981) 1.50
Mediator-induced activation of xanthine oxidase in endothelial cells. FASEB J (1989) 1.49
Requirements for leukocyte adhesion molecules in nephrotoxic nephritis. J Clin Invest (1993) 1.49
Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis. J Clin Invest (2000) 1.49
Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation. Am J Pathol (1997) 1.49
Chemoattractants of leukocytes, with special reference to lymphocytes. Fed Proc (1972) 1.48
Biochemical quantitation of the chemotactic factor inactivator activity in human serum. J Lab Clin Med (1979) 1.46
In vitro and in vivo stimulation of rat neutrophils and alveolar macrophages by immune complexes. Production of O-2 and H2O2. Am J Pathol (1983) 1.46
Congenital 21-hydroxylase deficiency as a new deletion mutation. Detection in a proband during subsequent prenatal diagnosis by HLA typing and DNA analysis. Hum Immunol (1992) 1.45
In vitro and in vivo dependency of chemokine generation on C5a and TNF-alpha. J Immunol (1999) 1.45
Protective effects of oligosaccharides in P-selectin-dependent lung injury. Nature (1993) 1.43
Mediators of ischemia-reperfusion injury of rat lung. Am J Pathol (1997) 1.43
Neutrophil-dependent, oxygen-radical mediated lung injury associated with acute pancreatitis. Ann Surg (1989) 1.43
Oxygen radical dependent lung damage following thermal injury of rat skin. J Trauma (1983) 1.41
Immune complex-induced lung and dermal vascular injury. Differing requirements for tumor necrosis factor-alpha and IL-1. J Immunol (1992) 1.41
Defective leukotaxis in patients with lepromatous leprosy. J Lab Clin Med (1976) 1.41
Chemotactic factor inactivators of human granulocytes. J Clin Invest (1977) 1.40
Evidence for the role of oxygen radicals in acute nephrotoxic nephritis. Lab Invest (1984) 1.40
Those nasty radicals. West J Med (1986) 1.39
Expression of monocyte chemoattractant protein-1 and macrophage inflammatory protein-1 after focal cerebral ischemia in the rat. J Neuroimmunol (1995) 1.39